News Releases

News Releases
Events
Presentations

Year

September 9, 2019

Bioventus Agrees to Nationwide Contract with UnitedHealthcare® Commercial Plans, Members Have Access to DUROLANE® and GELSYN-3®for Knee Osteoarthritis

DURHAM, NC – September 9, 2019 – Bioventus , a global leader in orthobiologic solutions, has agreed to a nationwide contract with UnitedHealthcare Employer & Individual commercial plans. Beginning October 1, 2019, UnitedHealthcare commercial plan members will have access to both DUROLANE and

August 13, 2019

Bioventus Launches DUROLANE® SJ (1mL) in Australia and New Zealand; Receives Expanded Indications for DUROLANE (3mL)

HOOFDDORP, THE NETHERLANDS – August 13, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE SJ (1mL) , and has received expanded indications for DUROLANE (3mL), its single-injection joint-fluid osteoarthritis (OA) treatment, in Australia and New Zealand.

June 6, 2019

Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics

DURHAM– June 6, 2019 – Bioventus , a global leader in orthobiologic solutions, has entered into a development collaboration agreemen t with MTF Biologics , the world’s largest tissue bank, to co-develop a next generation placental tissue product for the treatment of painful musculoskeletal

March 27, 2019

Bioventus Launches OSTEOAMP SELECT Fibers

DURHAM, NC – March 27, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEO AMP SELECT Fibers , an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.

January 29, 2019

Bioventus Launches DUROLANE in Malaysia

HOOFDDORP, THE NETHERLANDS – January 29, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market.

January 15, 2019

Bioventus Launches OSTEOMATRIX+® Biphasic Bone Graft

DURHAM, NC – January 15, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of

October 25, 2018

Susan M. Stalnecker Named to Bioventus Board of Managers

DURHAM, NC – October 25, 2018 – Bioventus , a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue.

October 2, 2018

Bioventus Receives ANVISA Approval to Market DUROLANE in Brazil and Selects Pfizer as Exclusive Distribution Partner

HOOFDDORP, THE NETHERLANDS – October 2, 2018 – Bioventus , a global leader in orthobiologic solutions, has received approval from Agência Nacional de Vigilância Sanitária (ANVISA) to market DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Brazil.

July 23, 2018

Bioventus Enters Into Definitive Agreement to Divest BMP Program

DURHAM, NC – July 23, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers, LLC (VB) , a private equity investment

March 5, 2018

Bioventus Launches DUROLANE in the US

DURHAM, NC – March 5, 2018 – Bioventus , a global leader in orthobiologic solutions, today launched DUROLANE , its single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA) .

First page
Previous page
…
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Next page
Last page

Displaying 131 - 140 of 144